• Elad Mashiach, Juan Diego Alzate, Fernando De Nigris Vasconcellos, Kenneth Bernstein, Bernadine R Donahue, Zane Schnurman, Jason Gurewitz, Lauren E Rotman, Sylvia Adams, Marleen Meyers, Ruth Oratz, Yelena Novik, Maryann J Kwa, Joshua S Silverman, Erik P Sulman, John G Golfinos, and Douglas Kondziolka.
• Department of Neurological Surgery, NYU Langone Health, New York University, New York , New York , USA.
• Neurosurgery. 2024 Jan 1; 94 (1): 154164154-164.

Background And ObjectivesMedian survival for all patients with breast cancer with brain metastases (BCBMs) has increased in the era of targeted therapy (TT) and with improved local control of intracranial tumors using stereotactic radiosurgery (SRS) and surgical resection. However, detailed characterization of the patients with long-term survival in the past 5 years remains sparse. The aim of this article is to characterize patients with BCBM who achieved long-term survival and identify factors associated with the uniquely better outcomes and to find predictors of mortality for patients with BCBM.MethodsWe reviewed 190 patients with breast cancer with 931 brain tumors receiving SRS who were followed at our institution with prospective data collection between 2012 and 2022. We analyzed clinical, molecular, and imaging data to assess relationship to outcomes and tumor control.ResultsThe median overall survival from initial SRS and from breast cancer diagnosis was 25 months (95% CI 19-31 months) and 130 months (95% CI 100-160 months), respectively. Sixteen patients (17%) achieved long-term survival (survival ≥5 years from SRS), 9 of whom are still alive. Predictors of long-term survival included HER2+ status ( P = .041) and treatment with TT ( P = .046). A limited number of patients (11%) died of central nervous system (CNS) causes. A predictor of CNS-related death was the development of leptomeningeal disease after SRS ( P = .025), whereas predictors of non-CNS death included extracranial metastases at first SRS ( P = .017), triple-negative breast cancer ( P = .002), a Karnofsky Performance Status of <80 at first SRS ( P = .002), and active systemic disease at last follow-up ( P = .001). Only 13% of patients eventually needed whole brain radiotherapy. Among the long-term survivors, none died of CNS progression.ConclusionPatients with BCBM can achieve long-term survival. The use of TT and HER2+ disease are associated with long-term survival. The primary cause of death was extracranial disease progression, and none of the patients living ≥5 years died of CNS-related disease.Copyright © Congress of Neurological Surgeons 2023. All rights reserved.

28 keywords...

hide…